Q BioMed (OTCMKTS:QBIO) Stock Rating Upgraded by Zacks Investment Research

Q BioMed (OTCMKTS:QBIO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage currently has a $0.50 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 16.28% from the company’s current price.

According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “

Separately, ValuEngine upgraded Q BioMed from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Shares of QBIO traded up $0.04 during trading hours on Friday, hitting $0.43. 131,446 shares of the company were exchanged, compared to its average volume of 60,362. The company has a market cap of $6.50 million, a price-to-earnings ratio of -0.64 and a beta of 3.85. The firm’s fifty day moving average is $0.46 and its 200 day moving average is $1.08. Q BioMed has a fifty-two week low of $0.34 and a fifty-two week high of $2.54.

Q BioMed (OTCMKTS:QBIO) last issued its earnings results on Tuesday, October 15th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05). Analysts expect that Q BioMed will post -0.64 EPS for the current fiscal year.

Q BioMed Company Profile

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer.

Further Reading: Market Indexes

Get a free copy of the Zacks research report on Q BioMed (QBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.